PCSK9 and melanoma: Previous experiments conducted on melanoma cells with LDL receptor (LDLR) deletion also found that tumor growth inhibition introduced by PCSK9 inhibition was not affected by host LDLR status or cholesterol levels, which is consistent with the notions [16].